|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||90.08 - 90.93|
|52 Week Range||77.82 - 91.79|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.14%|
The Health Care Select Sector SPDR (XLV) , the largest healthcare exchange traded fund by assets, is up nearly 3% over the past month and is closing in on record highs. Some market observers are betting healthcare will reach and exceed those all-time highs. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
The health care sector continues higher, with the SPDR Health Care Select Sector ETF (xlv) on track for the longest win streak in 3 1/2 years, as it holds its lead as the best performing S&P 500 (spx) sector over the past three months. The sector ETF (XLV) edged up 0.1% toward its ninth-straight gain, which would be the longest such streak since the nine-session win streak ended Feb. 23, 2015. The next best sector-ETF performer over that time is the SPDR Consumer Discretionary Select Sector ETF (xly) which is up 9.2%, while the S&P 500 (spx) has gained 6.0% the past three months.
At the sector level, technology ETFs often receive plenty of attention, but investors should not overlook the recent out-performance offered by healthcare equivalents. For example, over the past 90 days, ...
Health care stocks have made a sharp break to the upside so far in the third quarter, leading the S&P 500 Index (SPX) and outpacing tech stocks in the process. As measured by both the S&P 500 Health Care Index and the Health Care Select Sector SPDR ETF ( XLV), health care stocks closed Monday just 1.8% below their record highs set in January. "Overall they look quite good," said Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC.
On August 3, Mylan (MYL) stock ended the trading day at $38.45 per share, rising ~5.3% compared to the previous day’s closing price. Mylan released its Q1 2018 earnings results on May 9. Mylan is also facing some supply constraints for the EpiPen, its allergy product, due to supply delays from Pfizer (PFE).
MARKET PULSE Shares of Henry Schein Inc. (hsic) rallied 3.5% in premarket trade Monday, after the health care services company beat profit and sales expectations and raised its earnings outlook, while announcing restructuring actions that include job cuts and facility closings.
If the U.S. is stuck in an escalating trade war, stocks and sector-related ETFs with the highest domestic sales exposure in the U.S. should begin to stand out. “If trade tensions continue to rise and new ...
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.
DaVita (DVA) released its second-quarter earnings after the market closed on August 1. It surpassed Wall Street analysts’ estimates for revenues and EPS and reported non-GAAP EPS of $1.15 on revenues of $2.9 billion. The EPS estimate was $0.97 on revenues of $2.8 billion.
What Will Financial Markets Look for in July's Jobs Report? For the first half of the year, the job growth has averaged 215,000—compared to 182,000 during the same period last year. The job growth in June was broad-based with the private sector adding 202,000 jobs and governments adding 11,000.
DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.
Incyte (INCY) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS at $0.34 on revenues of $473.8 million in Q2 2018.
On July 18, 2018, Johnson & Johnson (JNJ) closed at $127.80. The stock fell ~1% from the previous day’s closing price of $129.11. On the previous day, JNJ stock had registered a rise of ~3.5% triggered by the strong Q2 2018 earnings results. The stock is currently trading ~14% lower than its 52-week high of $148.32 reported on January 17, 2018. The stock registered a 52-week low of $118.62 on May 29, 2018, on the news that the company was scrapping a Phase Ib/II trial for Darzalex for the treatment of advanced or metastatic NSCLC (non-small cell lung cancer).
Pfizer Inc. (pfe) said Tuesday it will create 450 new jobs, as it unveiled plans to build a new $465 million sterile injectable facility in Portage, Mich. The drugmaker said the new plant is part of its previously announced plan to invest $5 billion in U.S.-based capital projects, as a result of the Tax Cuts and Jobs Act enacted this year. Pfizer currently employs 2,200 people in Portage, about 2.4% of its total workforce of 90,400 employees, according to FactSet. Pfizer's stock rallied 1%.
One of the best-performing corners of the health care sector this year is the medical device and equipment space, and total returns confirm the sentiment. The two exchange traded funds dedicated to medical ...
On July 17, Johnson & Johnson (JNJ) reported its Q2 2018 earnings results. JNJ stock declined ~3.6% on the day. The company registered adjusted EPS (earnings per share) of $2.10, up ~14.8% on a YoY (year-over-year) basis. The adjusted net earnings in the quarter came in at $5.7 billion, a YoY rise of ~14%.
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
MARKET PULSE A policy being weighed by the Trump administration that could threaten drug price rebates, a widespread feature of the U.S. pharmaceutical system that largely benefits pharmaceutical middlemen, sent shares of those companies down in Thursday trade.
Technician Carter Worth, Cornerstone Macro, on whether CHURT is the new FANG. With CNBC's Brian Sullivan and the Fast Money traders, Tim Seymour, David Seaburg and Guy Adami.
JP Morgan's Marko Kolanovic sees a rotation out of growth and into value. With CNBC's Phil LeBeau and Scott Wapner, and the Fast Money traders, Pete Najarian, Karen Finerman, Steve Grasso and Guy Adami.